Shire’s $2.4bn oncology sell-off seen as Takeda spoiler
M&A, Oncology, Servier, Shire, Takeda
0 Comment
Move seen as attempt to fend off Takeda takeover
Takeda
Takeda looks for loans to fund $40bn Shire takeover
M&A, Rare diseases, Shire, Takeda
0 Comment
CEO Weber wants to turn Takeda into global pharma
Shire surges as Takeda weighs takeover bid
Shares in the UK-based Shire Pharma have surged upwards after Takeda has disclosed that it is considering a takeover bid.
Sanofi to pay back Philippines after Dengue vaccine problems
Dengue vaccine, infectious diseases, market access, safety, Sanofi, Takeda, vaccine
0 Comment
Japanese pharma set for transformation in 2018 – report
M&A, regulation, Takeda
0 Comment
Generics and biosimilars to drive growth, according to report.
Takeda to buy stem cell specialists TiGenix for $626m
European biotech, gastroenterology, M&A, Takeda, TiGenix
0 Comment
Decision follows EU regulators’ decision to back Crohn’s stem cell therapy
GW files cannabis-based epilepsy drug in EU and US
epilepsy, GW Pharma, neurology, Takeda
0 Comment
After Sativex disappointment, Epidiolex could transform GW’s fortunes.
Takeda interested in next-generation immuno-oncology deals
blood cancer, cancer, M&A, R&D, Takeda
0 Comment
Japanese firm wants to build presence in cancer